NetraMark and CAMH Collaborate to Advance AI in Schizophrenia Research

NetraMark Holdings Inc. and the Centre for Addiction and Mental Health (CAMH) have announced a significant collaboration aimed at enhancing research into schizophrenia and major depressive disorder. On December 16, 2025, the two organizations were recognized with the Ontario Research Fund – Research Excellence (ORF-RE) Award, which honors innovative research partnerships in Ontario.

This collaboration will utilize NetraMark’s AI-powered platform, NetraAI, within CAMH’s secure high-performance computing environment. The platform will analyze genetic and epigenetic data from studies focused on schizophrenia and major depressive disorder that are supported by the ORF-RE program. The primary goal is to identify distinct patient subpopulations, which can illuminate biological subtypes of psychiatric disorders and inform precision treatment strategies.

Enhancing Clinical Outcomes with AI

Dr. James Kennedy, Head of the Tanenbaum Centre for Pharmacogenetics at CAMH, emphasized the importance of this initiative. He stated, “This collaboration integrates NetraMark’s unique AI approach with CAMH’s deep genomic and clinical datasets to explore how genetic and epigenetic patterns influence treatment response. The insights generated will advance our understanding of the genes that alter a patient’s response to psychiatric medication.”

This partnership is expected to improve clinical trial outcomes for pharmaceutical sponsors in the psychiatric field. The installation of the NetraAI software is being managed by CAMH’s Research IT team, with support from NetraMark, ensuring that all analyses utilize de-identified patient data in accordance with strict data privacy and security protocols.

Broader Health-System Impacts

In addition to the main research focus, the collaboration will also assess an additional dataset from the Ontario Health Insurance Plan (OHIP). This analysis aims to evaluate cost-effectiveness and explore the broader impacts of personalized patient care within the health system.

Dr. Joseph Geraci, Founder and Chief Scientific & Technology Officer of NetraMark, expressed pride in the partnership. He noted, “Combining their datasets with NetraAI’s unique explainable AI framework allows us to uncover biologically grounded subpopulations that have previously eluded traditional analytics. We believe this work will contribute to next-generation precision-medicine approaches for mental health and improve clinical trial outcomes.”

NetraAI differentiates itself from traditional AI methods by employing focus mechanisms that categorize patient data into explainable and unexplainable subsets. This approach mitigates the risks of “overfitting,” which often leads to inaccurate insights. By leveraging explainable subsets, NetraAI aims to enhance the success rates of clinical trials and improve treatment efficacy.

NetraMark specializes in developing Generative Artificial Intelligence and Machine Learning solutions tailored for the pharmaceutical industry. Their innovative algorithms allow for the effective segmentation of patient data, enabling more accurate classifications related to drug sensitivity and treatment efficacy.

As this collaboration progresses, it stands to make a significant impact on the understanding and treatment of complex mental health disorders, ultimately aiming for a future where personalized medicine becomes the standard.

For further information regarding NetraMark and its initiatives, please refer to the publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR+).